NO20061681L - Terapeutiske bindingsmolekyler - Google Patents

Terapeutiske bindingsmolekyler

Info

Publication number
NO20061681L
NO20061681L NO20061681A NO20061681A NO20061681L NO 20061681 L NO20061681 L NO 20061681L NO 20061681 A NO20061681 A NO 20061681A NO 20061681 A NO20061681 A NO 20061681A NO 20061681 L NO20061681 L NO 20061681L
Authority
NO
Norway
Prior art keywords
ser
asn
amino acid
acid sequence
ile
Prior art date
Application number
NO20061681A
Other languages
English (en)
Inventor
Frank Kolbinger
Bruce M Hall
Jose Saldanha
Jose M Carballido Herrera
Andreas Aszodi
Silvia Gregori
Maria Grazia Roncarolo
Veronique Loux
Gregorio Aversa
Margit Jeschke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/666,332 external-priority patent/US20050069538A1/en
Priority claimed from GB0414309A external-priority patent/GB0414309D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20061681L publication Critical patent/NO20061681L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Et molekyl som omfatter minst ett antigenbindende sete, som omfatter i sekvens de hypervariable regionene CDR1, CDR2 og CDR3, nevnte CDR1 har aminosyresekvensen Asn-Tyr-Ile-Ile-His (NYIIH), nevnte CDR2 har aminosyresekvensen Tyr-Phe-Asn-Pro-Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe-Lys-Gly (YFNPYNHGTKYNEKFKG) og nevnte CDR3 har aminosyresekvensen Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr (SGPYAWFDT); for eksempel som videre omfatter i sekvens de hypervariable regionene CDR1', CDR2'og CDR3', CDRl'har aminosyresekvensen Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-Ser-Ile-Gln (RASQNIGTSIQ), CDR2'har aminosyresekvensen Ser-Ser-Ser-Glu-Ser-Ile-Ser (SSSESIS) og CDR3'har aminosyresekvensen Gln-Gln-Ser-Asn-Thr-Trp-Pro-Phe-Thr (QQSNTWPFT), for eksempel et kimært eller humanisert antistoff som er nyttig som farmasøytika.
NO20061681A 2003-09-18 2006-04-12 Terapeutiske bindingsmolekyler NO20061681L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/666,332 US20050069538A1 (en) 2003-09-18 2003-09-18 Therapeutic binding molecules
GB0414309A GB0414309D0 (en) 2004-06-25 2004-06-25 Organic compounds
PCT/EP2004/010471 WO2005026210A2 (en) 2003-09-18 2004-09-17 Therapeutic binding molecules

Publications (1)

Publication Number Publication Date
NO20061681L true NO20061681L (no) 2006-06-13

Family

ID=34315457

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061681A NO20061681L (no) 2003-09-18 2006-04-12 Terapeutiske bindingsmolekyler

Country Status (28)

Country Link
EP (1) EP1664122B1 (no)
JP (1) JP4762142B2 (no)
KR (1) KR20060079232A (no)
AR (2) AR045765A1 (no)
AT (1) ATE461219T1 (no)
AU (1) AU2004272289B2 (no)
BR (1) BRPI0414515A (no)
CA (1) CA2537217A1 (no)
CY (1) CY1110033T1 (no)
DE (1) DE602004026081D1 (no)
DK (1) DK1664122T3 (no)
EC (1) ECSP066432A (no)
ES (1) ES2341341T3 (no)
HR (1) HRP20100334T1 (no)
IL (1) IL173820A0 (no)
IS (1) IS8397A (no)
MA (1) MA28041A1 (no)
MY (1) MY143963A (no)
NO (1) NO20061681L (no)
NZ (1) NZ545605A (no)
PE (1) PE20060019A1 (no)
PL (1) PL1664122T3 (no)
PT (1) PT1664122E (no)
RU (1) RU2386639C2 (no)
SI (1) SI1664122T1 (no)
TN (1) TNSN06087A1 (no)
TW (1) TW200521231A (no)
WO (1) WO2005026210A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2502631A1 (en) 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
TWI579722B (zh) * 2015-02-17 2017-04-21 陳沛隆 藥物不良反應風險評估方法及其裝置
WO2016164502A1 (en) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
KR20230082055A (ko) * 2016-06-17 2023-06-08 마젠타 테라퓨틱스 인코포레이티드 세포의 고갈을 위한 조성물 및 방법
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
CN116724060A (zh) * 2020-07-24 2023-09-08 小利兰·斯坦福大学董事会 调节SIRPα介导的信号传导的组合物和方法
US20230374148A1 (en) 2020-10-15 2023-11-23 UCB Biopharma SRL Binding molecules that multimerise cd45
US12404315B2 (en) 2020-12-21 2025-09-02 Allogene Therapeutics, Inc. Protease-activating CD45-gate CAR
EP4433512A4 (en) 2021-11-19 2025-12-31 Univ Pennsylvania Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2170256C2 (ru) * 1991-07-25 2001-07-10 Айдек Фармасьютикалс Корпорейшн Рекомбинантное антитело, специфичное к cd4, способ его получения и фармацевтическая композиция для лечения псориаза
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BRPI0414515A (pt) 2006-11-07
AU2004272289B2 (en) 2008-09-18
SI1664122T1 (sl) 2010-07-30
EP1664122B1 (en) 2010-03-17
NZ545605A (en) 2009-03-31
PL1664122T3 (pl) 2010-08-31
IL173820A0 (en) 2006-07-05
JP4762142B2 (ja) 2011-08-31
WO2005026210A2 (en) 2005-03-24
PT1664122E (pt) 2010-05-10
DE602004026081D1 (de) 2010-04-29
TW200521231A (en) 2005-07-01
WO2005026210A3 (en) 2005-07-14
RU2386639C2 (ru) 2010-04-20
ES2341341T3 (es) 2010-06-18
MY143963A (en) 2011-07-29
AU2004272289A1 (en) 2005-03-24
EP1664122A2 (en) 2006-06-07
AR045765A1 (es) 2005-11-09
AR079458A2 (es) 2012-01-25
CY1110033T1 (el) 2015-01-14
MA28041A1 (fr) 2006-07-03
IS8397A (is) 2006-04-03
HRP20100334T1 (hr) 2010-07-31
RU2006112598A (ru) 2007-10-27
CA2537217A1 (en) 2005-03-24
HK1091844A1 (en) 2007-01-26
ATE461219T1 (de) 2010-04-15
DK1664122T3 (da) 2010-06-28
ECSP066432A (es) 2006-09-18
PE20060019A1 (es) 2006-02-27
TNSN06087A1 (en) 2007-10-03
JP2007529196A (ja) 2007-10-25
KR20060079232A (ko) 2006-07-05

Similar Documents

Publication Publication Date Title
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
BR0207151A (pt) Moléculas de aglutinação terapêuticas
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
HRP20181069T1 (hr) Antagonistička protutijela na il-17
JP2024054410A5 (no)
BR0318454A (pt) anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
BRPI0712953B8 (pt) anticorpos anti-nkg2a, seu uso, e composição farmacêutica
AR035581A1 (es) Anticuerpos para il-1beta humana
EP4527408A3 (en) Claudin-6 antibodies and drug conjugates
EP2796466A3 (en) Humanized antibody molecules specific for IL-31
TW200716182A (en) Antibodies directed to CD20 and uses thereof
NO20090877L (no) Antistoffer rettet mot alfaVbeta6 og anvendelser derav
CO6251370A2 (es) Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
DE602005022928D1 (de) Antikörper gegen gpnmb und ihre verwendungen
GEP20074222B (en) Antibodies to cd40
EP2377555A3 (en) Antibodies against vascular endothelial growth factor receptor-1
WO2006039258A3 (en) Human antibodies against parathyroid hormone
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
WO2007065037A3 (en) Antibodies against mmp-13 (collagenase-3) and uses thereof
TH102395B (th) โปรตีนจับที่จำเพาะสำหรับแฟกเตอร์เพื่อการเติบโตเช่นอินซูลินและการใช้โปรตีนจับเหล่านี้

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application